| Literature DB >> 31717513 |
Iulia Zoicas1, Johannes Kornhuber1.
Abstract
The appropriate display of social behaviors is essential for the well-being, reproductive success and survival of an individual. Deficits in social behavior are associated with impaired N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission. In this review, we describe recent studies using genetically modified mice and pharmacological approaches which link the impaired functioning of the NMDA receptors, especially of the receptor subunits GluN1, GluN2A and GluN2B, to abnormal social behavior. This abnormal social behavior is expressed as impaired social interaction and communication, deficits in social memory, deficits in sexual and maternal behavior, as well as abnormal or heightened aggression. We also describe the positive effects of pharmacological stimulation of the NMDA receptors on these social deficits. Indeed, pharmacological stimulation of the glycine-binding site either by direct stimulation or by elevating the synaptic glycine levels represents a promising strategy for the normalization of genetically-induced, pharmacologically-induced or innate deficits in social behavior. We emphasize on the importance of future studies investigating the role of subunit-selective NMDA receptor ligands on different types of social behavior to provide a better understanding of the underlying mechanisms, which might support the development of selective tools for the optimized treatment of disorders associated with social deficits.Entities:
Keywords: NMDAR agonists; NMDAR antagonists; inter-male aggression; maternal aggression; maternal care; mating behavior; social investigation; social recognition; ultrasonic vocalizations
Year: 2019 PMID: 31717513 PMCID: PMC6887971 DOI: 10.3390/ijms20225599
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Expression of NMDA receptors in animal models with impaired social behavior.
| Species | NMDA Receptor Functioning | Behavioral Deficit | References |
|---|---|---|---|
| NR1(neo-/-) mice | Expression of GluN1 only to 5% of normal levels | Impaired social interaction | [ |
| PV-selective NR1 knock-out mice | Loss of GluN1 subunit in parvalbumin-containing GABAergic interneurons during development | Impaired social interaction | [ |
|
| Selective elimination of GluN1 in 40%–50% of cortical and hippocampal GABAergic interneurons in early postnatal development, but not in the post-adolescent period | Impaired social interaction | [ |
| iFB knock-out mice | Inducible forebrain-specific deletion of GluN1 subunits | Impaired social interaction | [ |
| CA3 NR1 knock-out mice | Deletion of the GluN1 subunit gene in the ventral, but not the dorsal, CA3 pyramidal cells | Impaired social memory | [ |
| DG NR1 knock-out mice | Deletion of the GluN1 subunit gene in DG granule cells | Normal social memory | [ |
| GluN2B2A(CTD) mice | Increased postnatal forebrain expression of the GluN2A subunit | Impaired social memory | [ |
| GluN2A2B(CTD) mice | Increased postnatal forebrain expression of the GluN2B subunit | Enhanced social memory | [ |
| GluN2D knock-out mice | Deficient expression of the GluN2D subunit | Normal social interaction | [ |
| Grin1D481N mice | Chronic and developmentally diminished NMDA receptor glycine site occupancy (fivefold decrease in NMDA receptor glycine affinity) | Impaired social interaction | [ |
| Serine racemase knock-out mice | Impaired NMDA receptor function due to a 90% reduction in cortical D-serine | Impaired social interaction | [ |
| Hbegf knock-out mice | Reduced expression of hippocampal GluN1/GluN2-NMDA receptor subunits | Impaired maternal behavior | [ |
| Shank2 knock-out mice | Decreased function of the GluN2A- and GluN2B-containing NMDA receptors in the hippocampus | Impaired social interaction | [ |
| St8sia2 knock-out mice | Decreased NMDA receptor currents and decreased expression of GluN2B, but not of GluN1 and GluN2A, in the lateral amygdala | Abnormal (psychopathological) aggressive behavior | [ |
| Socially-isolated mice and rats | Increased GluN2A and GluN2B expression in the hippocampus | Impaired social interaction | [ |
| Mice during morphine withdrawal | Increased GluN2A and GluN2B expression in the frontal cortex | Increased inter-male aggression | [ |
NMDA, N-methyl-D-aspartate; NR1, GluN1 subunit; PV, parvalbumin; GABA, gamma aminobutyric acid; iFB, inducible forebrain-specific expression; CA3, cornu ammonis 3; DG, dentate gyrus; NR2, GluN2 subunit.
Effects of the NMDA receptor agonists and antagonists on social behavior in rodents.
| Action | Drug | Species | Behavioral Change | References |
|---|---|---|---|---|
|
| ||||
| Un-competitive NMDA receptor antagonists | MK-801 | Mice and rats | Decreased social interaction | [ |
| NMDA receptor antagonist | Memantine | IRSp53 knock-out mice | Reduced social interaction deficits | [ |
| GluN2A-preferring antagonist | PEAQX | Rats | Decreased social interaction | [ |
| GluN2B-preferring antagonist | Ifenprodil | Rats | Decreased social interaction | [ |
| Full agonist of the glycine-binding site | D-serine | Autistic Balb/c mice | Reduced social interaction deficits | [ |
| Partial agonist of the glycine-binding site | D-cycloserine | Autistic Balb/c mice | Reduced social interaction deficits | [ |
| GlyT1 inhibitor | TASP0315003 | Postnatally PCP-treated mice | Reduced social interaction deficits | [ |
|
| ||||
| Un-competitive NMDA receptor antagonists | PCP | Rats | Reduced 50 kHz USV | [ |
| Un-competitive NMDA receptor antagonist | MK-801 | Rat pups | Reduced separation-induced USV | [ |
| Competitive NMDA receptor antagonists | AP5 | Rat pups | Reduced separation-induced USV | [ |
| NMDA receptor antagonists | Memantine | Rat pups | Increased separation-induced USV at low to moderate doses and reduced separation-induced USV at high doses | [ |
| Glycine antagonist | 5,7-DCKA | Rat pups | Reduced separation-induced USV | [ |
| NMDA receptor agonist | NMDA | Rat pups | Increased separation-induced USV | [ |
| Partial agonist of the glycine-binding site | D-cycloserine | Prenatally VPA-treated rats | Reduced deficits in social communication | [ |
|
| ||||
| Un-competitive NMDA receptor antagonists | MK-801 | Rats and mice | Impaired social memory | [ |
| Full agonists of the glycine-binding site | D-serine | Rats | Enhanced social memory | [ |
| GlyT1 inhibitors | NFPS | Rats | Enhanced social memory | [ |
|
| ||||
| Un-competitive NMDA receptor antagonists | MK-801 | Socially-isolated mice | Decreased inter-male aggression | [ |
| NMDA receptor antagonists | Memantine | Naïve and morphine-treated mice | Reduced morphine withdrawal-facilitated aggression, but did not affect inter-male aggression in naïve mice | [ |
| Partial agonist of the glycine-binding site | D-cycloserine | Mice | Decreased inter-male aggression | [ |
|
| ||||
| Un-competitive NMDA receptor antagonist | MK-801 | Male and female rats | Impaired sexual behavior | [ |
|
| ||||
| Un-competitive NMDA receptor antagonist | MK-801 | Rats | Blocked experienced-based facilitation of maternal care | [ |
| Competitive NMDA receptor antagonist | AP5 | Mice | Impaired maternal aggression, but not maternal care | [ |
| NMDA receptor agonist | NMDA | Mice | Impaired maternal care | [ |
NMDA, N-methyl-D-aspartate; MK-801, 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate; MK-801, dizocilpine, 5R,10S-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate; PCP, phencyclidine; memantine, 1-amino-3,5-dimethyladamantane hydrochloride; PEAQX, {NVP-AAM o77; P-[[[(15)-1-(4-Bromophenyl)ethyl]amino](1,2,3,4-tetrahydro-2,3-dioxo-5-qyuinoxalinyl)methyl]phosphoric acid tetrasodium salt}; polyI:C, polyriboinosinic-polyribocytidilic acid; VPA, valproic acid; GlyT1, glycine transporter 1; TASP0315003, 3-chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidin-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide; VU0410120, 2,4-dichloro-N-((4-(cyclopropylmethyl)-1-(ethyl sulfonyl)piperidin-4-yl)methyl)benzamide; USV, ultrasonic vocalizations; tiletamine, 2-ethylamino-2-thiophen-2-yl-cyclohexan-1-one; AP5, D,L-amino-phosphonovaleric acid; AP7, 2-amino-7-phosphonoheptanoic acid; CPP, 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid; memantine, 1-amino-3,5-dimethyladamantane hydrochloride; 5,7-DCKA, 5,7-dichlorokynurenic acid; PQQ, pyrroloquinoline quinone; NFPS, N[3-(4′-flurophenyl)-3-(4′-phenylphenoxy) propyl]sarcosine; MRZ 2/579, 1-amino-1,3,3,5,5-pentamethyl-cyclohexan hydrochloride.